middle.news
How Arovella’s $19.4M Boost Fuels CAR-iNKT Cancer Therapy Breakthrough
9:02am on Friday 23rd of January, 2026 AEDT
•
Biotechnology
Read Story
How Arovella’s $19.4M Boost Fuels CAR-iNKT Cancer Therapy Breakthrough
9:02am on Friday 23rd of January, 2026 AEDT
Key Points
Filed IND application for ALA-101 targeting CD19-positive blood cancers
Selected SAPRO as CRO for phase 1 clinical trial start-up
Demonstrated potent activity of novel CLDN18.2-targeting CAR for solid tumours
Exercised option to license additional CAR and iNKT technologies from Baylor College of Medicine
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AROVELLA THERAPEUTICS (ASX:ALA)
OPEN ARTICLE